BioTime and Subsidiary LifeMap Sciences Announce Release of Enhanced LifeMap BioReagents™ Portal Offering Additional PureStem™ Human Progenitor Cells Including Those for Diabetes Research ALAMEDA, Calif.--(BUSINESS WIRE)--May. 7, 2013--
BioTime, Inc. (NYSE MKT: BTX) and subsidiary, LifeMap Sciences, today
announced the release of the enhanced LifeMap BioReagents™ portal
(http://bioreagents.lifemapsc.com/)
featuring an improved user interface, product descriptions, and customer
support options, as well as the addition of new PureStem™
progenitor cells to the site. These novel progenitors provide new and
unique tools for researchers to study developmental biology, tissue
genesis and regenerative medicine, demonstrating purity in culture and
unique gene expression. Among the new product offerings are novel PureStem™
progenitor cells such as the E72 cells capable of differentiating into
betatrophin-expressing adipocytes, which may be useful in diabetes
research.
Via LifeMap BioReagents™, researchers in academia,
research hospitals, and biotech and pharma companies can access and
purchase BioTime’s research products, including PureStem™ human
progenitor cells, PureStem™ packages, clinical and research grade
human embryonic stem cell (hES) lines, culture media, and cell
differentiation kits. As of April, the portal also offers select
recombinant proteins, including growth factors, signaling molecules,
differentiation factors, cytokines and chemokines that complement
BioTime research product lines.
LifeMap BioReagents™ is integrated with LifeMap’s integrated
database suite products LifeMap Discovery™, GeneCards®
and MalaCards, thereby providing all biomedical researchers
accessing these databases a means of identifying stem cell reagents that
can enhance research and discovery efforts in a variety of fields,
including stem cell research, developmental biology, mechanisms of
various human diseases, drug discovery and therapeutic discovery and
development. According to Google Analytics, the sites have generated
more than 2,000,000 unique visitors with more than 13,000,000 page views
in the past 12 months. LifeMap holds an exclusive, worldwide license
from Yeda Research and Development Company Ltd., the commercial arm of
the Weizmann Institute of Science, to market GeneCards® (www.genecards.org),
the human gene compendium, and MalaCards (www.malacards.org),
a database with nearly 17,000 human disease entries.
“The diversity, purity, and scalability of PureStem™ cells
combined with the continued discovery process underway at BioTime, where
novel differentiation pathways are being defined, gives us a growing
opportunity to market these products in the research sector,” said
Jeffrey Janus, Vice President of Sales and Marketing at BioTime. “This
is an exciting beginning to a new era in stem cell research. In
combination with the LifeMap integrated database suite, our embryonic
progenitors will provide researchers a unique new set of products to
make novel clinical discoveries and advance the field of regenerative
medicine.”
“We are pleased to continue the expansion and enhancement of our
e-Commerce portal,” stated Yaron Guan-Golan, Head of Marketing at
LifeMap Sciences. “Our growing user base will have improved access to
our product portfolio via LifeMap BioReagents™. The addition of PureStem™
human progenitor lines, including cell types targeting the hottest new
research in diabetes, will increase LifeMap BioReagents™ brand
awareness and the quality of our offering to the global biomedical
research community.”
About LifeMap Sciences, Inc.
LifeMap Sciences’ (www.lifemapsc.com)
core technology and business is based on its integrated database suite,
the discovery platform for biomedical and stem cell research. This
platform includes GeneCards®, the leading human gene
database; LifeMap Discovery™, the database of embryonic
development, stem cell research and regenerative medicine; and MalaCards,
the human disease database. According to Google Analytics, the sites
have generated more than 2,000,000 unique visitors with more than
13,000,000 page views in the past 12 months. LifeMap Sciences also
markets PanDaTox, an innovative, recently developed, searchable
database that can aid in the discovery of new antibiotics and
biotechnologically beneficial products.
In addition to database offerings, LifeMap Sciences is BioTime’s
principal marketing subsidiary for research products, including PureStem™
human progenitor cell lines, GMP human embryonic stem (hES) cell lines, ESpan™
growth media for progenitor cell lines, and cell differentiation media
for non-therapeutic uses, via its LifeMap BioReagents™ portal.
LifeMap Sciences utilizes its databases as part of its online marketing
strategy to reach life sciences researchers at biotech and
pharmaceutical companies and at academic institutions and research
hospitals worldwide.
In a therapeutic discovery collaboration with BioTime, LifeMap’s
scientists utilize LifeMap’s proprietary platform, including LifeMap
Discovery™, its stem cell database along with the GeneCards®
and MalaCards integrated database suite, to aid in the
development of BioTime’s proprietary PureStem™ human progenitor
cell lines into products for the treatment of human diseases, especially
degenerative diseases that might be treatable with cell replacement
therapies. The LifeMap Discovery™ platform will be used to select
the progenitor cell lines that are most likely to be useful in
developing cell-based regenerative medicine therapies for a wide range
of diseases.
About BioTime, Inc.
BioTime, headquartered in Alameda, California, is a biotechnology
company focused on regenerative medicine and blood plasma volume
expanders. Its broad platform of stem cell technologies is enhanced
through subsidiaries focused on specific fields of application. BioTime
develops and markets research products in the fields of stem cells and
regenerative medicine, including a wide array of proprietary PureStem™
cell lines, HyStem® hydrogels, culture media, and
differentiation kits. BioTime is developing Renevia™ (formerly
known as HyStem®-Rx), a biocompatible,
implantable hyaluronan and collagen-based matrix for cell delivery in
human clinical applications. BioTime's therapeutic product development
strategy is pursued through subsidiaries that focus on specific organ
systems and related diseases for which there is a high unmet medical
need. BioTime's majority owned subsidiary Cell Cure Neurosciences Ltd.
is developing therapeutic products derived from stem cells for the
treatment of retinal and neural degenerative diseases. BioTime's
subsidiary OrthoCyte Corporation is developing therapeutic applications
of stem cells to treat orthopedic diseases and injuries. Another
subsidiary, OncoCyte Corporation, focuses on the diagnostic and
therapeutic applications of stem cell technology in cancer, including
the diagnostic product PanC-Dx™ currently being developed for the
detection of cancer in blood samples. ReCyte Therapeutics, Inc. is
developing applications of BioTime's proprietary induced pluripotent
stem cell technology to reverse the developmental aging of human cells
to treat cardiovascular and blood cell diseases. BioTime's subsidiary
LifeMap Sciences, Inc. markets GeneCards®, the leading
human gene database, as part of an integrated database suite that also
includes the LifeMap Discovery™ database of embryonic
development, stem cell research and regenerative medicine, and MalaCards,
the human disease database. LifeMap Sciences also markets BioTime
research products and PanDaTox, an innovative, recently
developed, searchable database that can aid in the discovery of new
antibiotics and biotechnologically beneficial products. Asterias
Biotherapeutics, Inc. is a new subsidiary being used to acquire the stem
cell assets of Geron Corporation, including patents and other
intellectual property, biological materials, reagents and equipment for
the development of new therapeutic products for regenerative medicine.
BioTime's lead product, Hextend®, is a blood plasma
volume expander manufactured and distributed in the U.S. by Hospira,
Inc. and in South Korea by CJ CheilJedang Corporation under exclusive
licensing agreements. Additional information about BioTime can be found
on the web at www.biotimeinc.com.
Forward-Looking Statements
Statements pertaining to future financial and/or operating results,
future growth in research, technology, clinical development, and
potential opportunities for BioTime and its subsidiaries, along with
other statements about the future expectations, beliefs, goals, plans,
or prospects expressed by management constitute forward-looking
statements. Any statements that are not historical fact (including, but
not limited to statements that contain words such as "will," "believes,"
"plans," "anticipates," "expects," "estimates") should also be
considered to be forward-looking statements. Forward-looking statements
involve risks and uncertainties, including, without limitation, risks
inherent in the development and/or commercialization of potential
products, uncertainty in the results of clinical trials or regulatory
approvals, need and ability to obtain future capital, and maintenance of
intellectual property rights. Actual results may differ materially from
the results anticipated in these forward-looking statements and as such
should be evaluated together with the many uncertainties that affect the
business of BioTime and its subsidiaries, particularly those mentioned
in the cautionary statements found in BioTime's Securities and Exchange
Commission filings. BioTime disclaims any intent or obligation to update
these forward-looking statements.
To receive ongoing BioTime corporate communications, please click on the
following link to join our email alert list: http://phx.corporate-ir.net/phoenix.zhtml?c=83805&p=irol-alerts
Source: BioTime, Inc.
BioTime, Inc.
Judith Segall, 510-521-3390 ext. 301
jsegall@biotimemail.com
or
LifeMap
Sciences, Inc.
Kenneth Elsner, 781-826-7719
COO
ke@lifemapsc.com
View printer-friendly version